Holding(s) in Company

Abingdon Health

02/12/2025 15:08

RNS Number : 9376J

Abingdon Health PLC

02 December 2025

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Holdings in Company

 

York, U.K. 2 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid tests and med-tech, has been made aware of the following changes in holdings of its ordinary shares of 0.025p each in the Company ("Ordinary Shares") following the recently completed Placing and Retail Offer:

 

·      Chris Yates, who holds an interest of 7,088,844 Ordinary Shares, now holds less than 3 per cent. of the Company's currently issued share capital.

·      CatenaLucis LLC, who hold an interest of 7,088,488 Ordinary Shares, now holds less than 3 per cent. of the Company's currently issued share capital.

·      Thornapple LLP, who holds an interest of 6,113,124 Ordinary Shares, now holds less than 3 per cent. of the Company's currently issued share capital.

 

Enquiries:

 

Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand, ExecutiveChairman
Via Walbrook PR
Tom Hayes, CFO
Zeus (Sole Broker and Nominated Adviser)
Tel: +44 (0)20 3829 5000
Antonio Bossi / Jacob Walker (Corporate Finance)
Nick Searle/Fraser Marshall (Corporate Broking)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654


 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

 

The Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success".  Abingdon Analytical Ltd offers performance evaluation for lateral flow and other in vitro diagnostic assays from its Doncaster laboratory. 

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

 

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

 

 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
Abingdon Health plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify) iii:
3. Details of person subject to the notification obligationiv
Name
Chris Yates
City and country of registered office (if applicable)
4. Full name of shareholder(s)(if different from 3.)v
Name
Chris Yates
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
31 October 2025
6. Date on which issuer notified (DD/MM/YYYY):
1 December 2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% ofvoting rights throughfinancial instruments
 (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B)vii
Resulting situation on the date on which threshold was crossed or reached
Below 3%
Below 3%
Position of previous notification (if
applicable)
3.7%
3.7%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
 shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
SUBTOTAL 8. A
Below 3%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Physical or cash
Settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2


 

9. Information in relation to the person subject to the notification obligation(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Fullchain of controlled undertakings through which the voting rights and/or the
 financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)xiv
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi


 

Place of completion
York, UK
Date of completion
1 December 2025

 

 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
Abingdon Health plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify) iii:
3. Details of person subject to the notification obligationiv
Name
CatenaLucis LLC
City and country of registered office (if applicable)
4. Full name of shareholder(s)(if different from 3.)v
Name
CatenaLucis LLC
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
31 October 2025
6. Date on which issuer notified (DD/MM/YYYY):
1 December 2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% ofvoting rights throughfinancial instruments
 (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B)vii
Resulting situation on the date on which threshold was crossed or reached
Below 3%
Below 3%
Position of previous notification (if
applicable)
3.7%
3.7%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
 shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
SUBTOTAL 8. A
Below 3%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Physical or cash
Settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2


 

9. Information in relation to the person subject to the notification obligation(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Fullchain of controlled undertakings through which the voting rights and/or the
 financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)xiv
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi


 

Place of completion
Madison, WI, USA
Date of completion
1 December 2025

 

 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
Abingdon Health plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify) iii:
3. Details of person subject to the notification obligationiv
Name
Thornapple LLP
City and country of registered office (if applicable)
4. Full name of shareholder(s)(if different from 3.)v
Name
Thornapple LLP
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
31 October 2025
6. Date on which issuer notified (DD/MM/YYYY):
1 December 2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% ofvoting rights throughfinancial instruments
 (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B)vii
Resulting situation on the date on which threshold was crossed or reached
Below 3%
Below 3%
Position of previous notification (if
applicable)
3.2%
3.2%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
 shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
SUBTOTAL 8. A
Below 3%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Physical or cash
Settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2


 

9. Information in relation to the person subject to the notification obligation(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Fullchain of controlled undertakings through which the voting rights and/or the
 financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)xiv
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi


 

Place of completion
Madison, WI, USA
Date of completion
1 December 2025

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
HOLTTBATMTMMBAA